Toggle Main Menu Toggle Search

Open Access padlockePrints

Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts

Lookup NU author(s): Professor David Burn



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Background Cardiovascular disease (CVD) influences phenotypic variation in Parkinson's disease (PD), and is usually an indication for statin therapy. It is less clear whether cardiovascular risk factors influence PD phenotype, and if statins are prescribed appropriately.Objectives To quantify vascular risk and statin use in recent-onset PD, and examine the relationship between vascular risk, PD severity and phenotype.Methods Cardiovascular risk was quantified using the QRISK2 calculator (high >= 20%, medium >= 10 and <20%, low risk <10%). Motor severity and phenotype were assessed using the Movement Disorder Society Unified PD Rating Scale (UPDRS) and cognition by the Montreal cognitive assessment.Results In 2909 individuals with recent-onset PD, the mean age was 67.5 years (SD 9.3), 63.5% were men and the mean disease duration was 1.3 years (SD 0.9). 33.8% of cases had high vascular risk, 28.7% medium risk, and 22.3% low risk, while 15.2% of cases had established CVD. Increasing vascular risk and CVD were associated with older age (p<0.001), worse motor score (p<0.001), more cognitive impairment (p<0.001) and worse motor phenotype (p=0.021). Statins were prescribed in 37.2% with high vascular risk, 15.1% with medium vascular risk and 6.5% with low vascular risk, which compared with statin usage in 75.3% of those with CVD.Conclusions Over 60% of recent-onset PD patients have high or medium cardiovascular risk (meriting statin usage), which is associated with a worse motor and cognitive phenotype. Statins are underused in these patients, compared with those with vascular disease, which is a missed opportunity for preventive treatment.

Publication metadata

Author(s): Swallow DMA, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, Ruffmann C, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Hu MTM, Grosset DG, PRoBAND Clinical Consortium

Publication type: Article

Publication status: Published

Journal: Journal of Neurology, Neurosurgery and Psychiatry

Year: 2016

Volume: 87

Issue: 11

Pages: 1183-1190

Print publication date: 01/11/2016

Online publication date: 26/09/2016

Acceptance date: 17/07/2016

Date deposited: 12/01/2017

ISSN (print): 0022-3050

ISSN (electronic): 1468-330X

Publisher: BMJ Group


DOI: 10.1136/jnnp-2016-313642


Altmetrics provided by Altmetric


Funder referenceFunder name
NIHR Oxford Biomedical Research Centre
National Institute for Health Research (NIHR) Dementias and Neurodegenerative Diseases Research Network (DeNDRoN)
NIHR Biomedical Research Centre in Cambridge
NIHR Newcastle Biomedical Research Unit
10.13039/501100000304Parkinson's UK
J-1101Parkinson's UK
J-1403Parkinson's UK
SC042915Michael's Movers for Parkinson's (Registered Charity)